• Publications
  • Influence
SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
It is demonstrated that WIN 55,212-2 is an agonist and SR141716A is an inverse agonist in this system. Expand
The perceived effects of smoked cannabis on patients with multiple sclerosis.
The survey findings will aid in the design of a clinical trial of cannabis or cannabinoid administration to MS patients or to other patients with similar signs or symptoms. Expand
Controlled clinical trial of cannabidiol in Huntington's disease
CBD, at an average daily dose of about 700 mg/day for 6 weeks, was neither symptomatically effective nor toxic, relative to placebo, in neuroleptic-free patients with Huntington's Disease. Expand
Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice.
The differential effects of CBD suggest that the cannabinoid acts to inhibit seizure spread in the CNS by an action on GABA, but not glycine, mechanisms. Expand
Enantiomeric cannabinoids: stereospecificity of psychotropic activity
The 1,1-dimethylheptyl homolog of (−)-(3R,4R)-7-hydroxy-delta-6-tetrahydrocannabinol (compoundII) is highly psychotropic in mice, rats and pigeons. The (+)-(3S,4S) enantiomer (III) was found to beExpand
Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
Efficacy values are a better measure of drug-mediated functional responses compared with measurements of drug potency because they relate receptor occupancy to functional responses. Expand
AM630 antagonism of cannabinoid-stimulated [35S]GTPγS binding in the mouse brain
Results clearly demonstrate that AM630 exerts cannabinoid receptor antagonist properties in the brain. Expand
Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders
  • P. Consroe
  • Medicine
  • Neurobiology of Disease
  • 1 December 1998
These endogenous structures and chemicals and mechanisms are potentially new pathophysiologic substrates, and targets for novel cannabinoid treatments, of several neurological disorders. Expand
delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain.
This is the first report demonstrating that delta 9-tetrahydrocannabinol acts as a partial agonist in stimulating [35S]GTP gamma S binding in the mouse brain. Expand
Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice.
A novel, affinity-purified, antigen binding fragment (Fab) antivenom (FabAV) for Crotalidae venom poisoning has been produced from the sera of sheep, and the results indicate that FabAV is 3.1-9.6 times more potent than ACP for the prevention of lethality of the nine United States venoms tested. Expand